Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Frozen embryo transfer: one extra day could boost success rates

NCT ID NCT05980091

Knowledge-focused Sponsor: ART Fertility Clinics LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether transferring a frozen embryo on day 6 or day 7 of progesterone treatment leads to more live births. It includes 316 women aged 18-43 who have at least one high-quality, genetically normal embryo. Researchers will track pregnancy and miscarriage rates to find the optimal timing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Estradiol valerate and progesterone
What this could lead to
If successful, this could help doctors choose the best day to transfer embryos, potentially improving pregnancy and live birth rates for women using frozen embryos.
What could go wrong
This is an early-phase study that is currently suspended, so results are not yet available. The timing difference may not significantly affect outcomes, and individual factors could still play a large role.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 316 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 43 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 18 years to 43 years. * Having at least 1 euploid cryopreserved day 6 blastocyst of at least Grade BB quality. * Endometrial trilaminar appearance on the day of progesterone start Exclusion Criteria: * Uterine abnormality * Hydrosalpinx * Asherman syndrome * Any known contraindications or allergy to oral estradiol or progesterone. * Intention to treat : exclusion factors : 1. Spontaneous ovulation HRT cycle 2. Discontinuation of HRT medication

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fertility issues are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

female infertility infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fertility issues Infertility Infertility, female

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ART Fertility Clinics Dubai

    Dubai, United Arab Emirates

  • ART Fertility Clinics LLC

    Abu Dhabi, Abu Dhabi Emirate, 60202, United Arab Emirates

More trials for these conditions

Other studies related to the condition(s) this trial covers.